July 30, 2021 - ROSEN LOGO.jpg
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Intel Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – INTC
May 08, 2024 16:11 ET | The Rosen Law Firm PA
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Intel...
PECOHorizontalLogoBlue.png
Phillips Edison & Company Announces Pricing of Offering of $350 Million Aggregate Principal Amount of 5.750% Senior Unsecured Notes Due 2034
May 08, 2024 16:10 ET | Phillips Edison & Company, Inc.
CINCINNATI, May 08, 2024 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO” or the “Company”), one of the nation’s largest owners and operators of grocery-anchored...
sitime-logo-PNG-med.png
SiTime Reports First Quarter 2024 Financial Results
May 08, 2024 16:10 ET | SiTime
SANTA CLARA, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- SiTime Corporation, (Nasdaq: SITM), the Precision Timing company, today announced financial results for the first quarter ended March 31, 2024. ...
Oculis logo.png
Oculis Reports Q1 2024 Financial Results and Provides Company Updates
May 08, 2024 16:10 ET | Oculis Holding AG
ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Clinical programs progressing as planned with initiation of second OCS-01 Phase 3 DIAMOND-2 trial in Diabetic Macular Edema (DME) and completion of...
IGM logo trademark 03.25.22.jpg
IGM Biosciences Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 08, 2024 16:10 ET | IGM Biosciences, Inc.
- Enrollment target exceeded in aplitabart randomized colorectal cancer clinical trial - - Enrollment completed in first dose cohort in imvotamab rheumatoid arthritis clinical trial - MOUNTAIN VIEW,...
CytomX Logo.jpg
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
May 08, 2024 16:10 ET | CytomX Therapeutics Inc.
- CX-904 demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall - - Encouraging initial...
Tsakos.jpg
TEN Ltd. Announces the Filing of Form 20-F With the SEC
May 08, 2024 16:10 ET | Tsakos Energy Navigation
ATHENS, Greece, May 08, 2024 (GLOBE NEWSWIRE) -- TEN, Ltd. (TEN) (NYSE: TNP) (the “Company”) announced today that its Annual Report on Form 20-F for the year ended December 31, 2023, has been filed...
Investor - Red.png
Profire Energy Reports Financial Results for First Quarter 2024
May 08, 2024 16:10 ET | Profire Energy, Inc.
LINDON, Utah, May 08, 2024 (GLOBE NEWSWIRE) -- Profire Energy, Inc. (NASDAQ: PFIE), a technology company (the "Company") that provides solutions which enhance the efficiency, safety, and reliability...
logo-blue (1).png
Taboola to Present in Upcoming Investor Conferences
May 08, 2024 16:10 ET | Taboola, Inc.
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Taboola (Nasdaq: TBLA), a global leader in powering recommendations for the open web, today announced that members of its management team will participate...
ContextLogic-Logo-2.png
ContextLogic Inc. Reports First-Quarter 2024 Financial Results
May 08, 2024 16:10 ET | ContextLogic Inc.
OAKLAND, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- ContextLogic Inc. (Nasdaq: WISH) (“ContextLogic,” the “Company,” “we” or “our”) today reported its financial results for the quarter ended March 31,...